Provided by ReachBio

Hematopoietic Cancer Stem Cells and Leukemic Progenitor Cells

For various hematological diseases (e.g. chronic myeloid leukemia, acute myeloid leukemia, multiple myeloma, lymphomas), the molecular abnormalities and perturbed signaling pathways that give rise to these diseases have, in recent years, been elucidated.

In many, if not all forms of cancer, a small number of slowly dividing, self-renewing cancer stem cells give rise to abundant and rapidly dividing diseased cells. Targeted killing of the cancer stem cells, while retaining the normal hematopoietic progenitors, is a new focus of research, aiming to develop more effective and less toxic cancer treatments.

Our Assay Services Include:

services6

AML | Acute Myeloid Leukemia Progenitor Assays
Common Applications for AML-blast like CFC:
  • Predict compound induced killing
  • Predict targeted cell killing
  • Evaluate effects of single agents or combined therapies

 

 

 

ALL | Acute Lymphoblastic Leukemia Progenitor Assays
Common Applications for ALL-CFC:
  • Predict compound induced killing
  • Predict targeted cell killing
  • Evaluate effects of single agents or combined therapies
 

 

CML | Chronic Myelogenous Leukemia Progenitor Assays
 Common Applications for CML-CFC:
services7

  • Predict compound induced killing
  • Predict targeted cell killing
  • Evaluate effects of single agents or combined therapies

 

 

 
 
CLL | Chronic Lymphocytic Leukemia Progenitor Assays
Common Applications for CLL-CFC:
  • Predict compound induced killing
  • Predict targeted cell killing
  • Evaluate effects of single agents or combined therapies
 
 
MM | Multiple Myeloma Progenitor Assays
services8
Common Applications for MM-CFC:
    • Predict compound induced killing
    • Predict targeted cell killing
    • Evaluate effects of single agents or combined therapies

 

 

NHL, MCL, DLBCL | Lymphoma Progenitor Assays
Common Applications:
  • Predict compound induced killing
  • Predict targeted cell killing
  • Evaluate effects of single agents or combined therapies

 

PV | Polycythemia Vera Progenitor Assays
Common Applications for Erythroid Independant CFC proliferation:
  • Predict compound induced killing
  • Predict targeted cell killing
  • Evaluate effects of single agents or combined therapies

 

 

AA | Aplastic Anemia

Aplastic anemia is a disease in which the bone marrow, and the blood stem cells that reside there, are damaged. Aplastic anemia is also called “bone marrow failure”. In this disease the marrow microenvironment (bone marrow stroma) on which the cells reside is impaired. The damage may be caused by exposure to chemicals, drugs, radiation, infection or immune disease. In some cases, the disease is inherited, but in half the cases, the cause is unknown.

Common Applications:

 

MDS | Myelodysplastic Syndromes

The MDS’s are hematological medical conditions with ineffective production of blood cells. They can be quite varied based on the type and severity of the disease. For some people, their quality of life and life span is not altered, but for others, the number and quality of blood-forming cells decline irreversibly which causes a significant reduction in multiple cell types and may also induce bone marrow failure.

Common Applications:
2016_09_21_21

 

Did You Know?

Patient Samples and CFU-L Assays

We have the ability to monitor cancer stem cells in patients over the course of a clinical trial using in vitro assays with cells from patients. We can also assess the differential toxicity of compounds on cancer stem cells (leukemic colony forming cells) compared to normal hematopoietic progenitor cells.  > Learn more

We can culture various hematopoietic cancer stem and/or progenitor cells in leukemic CFU-L (colony-forming cell) assays and evaluate the effects of test compounds on these cells. CONTACT US to learn more about our assay platform.